Rebel
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Honestly, Janice. You really need to do some research on Dr. Schena and microarrays and human genomes and what this company is all about. Comparing Arrayit to Theranos is so disrespectful and an INSULT to Arrayit's incredible technology and Dr. Schena's life's work. It is simply not fair to disparage Arrayit without having a basic understanding of what this company is really all about.
No need to remind us of the delayed financials. Everybody KNOWS.
No, Janice. They are not "just processing the results." They are actually conducting the tests. ARYC's "proprietary finger stick microarray allergy testing platform" is what is being used in their clinical lab.
No, it's true. The DD is on this very board and you should take some time to find it and then read all about it.
ARYC plans to PURCHASE the entire building and they are current with the rent, which by the way, is VERY expensive.
You see, the company is transitioning from largely R & D to largely lab services, and after loads of hard work, it is all coming together. I don't care if you buy or not, but I never buy stock in a company I hate, but that's just me.
Shares are cheap enough. All "nonbelievers" should be thrilled with these prices.
You haven't a clue as to where things stand with ANY of the major pharmacies and/or retailers with clinics. I do NOT believe you have attended any of the meetings or have been involved with negotiations or been privy to any insider information. And these things don't happen overnight you know.
It makes no sense to BOO EVERYTHING going on at Arrayit.
Ha ha. YOU do NOT know that.
Who could this be? July 02, 2018 (GLOBE NEWSWIRE) Sunnyvale, CA –- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’’s largest chains of retail stores. The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing. Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies. The test results were reviewed and approved by the retail chain’s Chief Medical Officer.
Arrayit allergy testing is particularly suitable for large retail chains because convenient finger stick sampling allows customers to integrate a physician-ordered allergy test into their real-time shopping experience. The test results, together with patient symptoms and medical history, enable in-store doctors to make personalized medical recommendations about allergy and asthma treatments and medicines, which are also conveniently provided by the retailer. The retail chain, which reports revenues exceeding $50,000,000,000 ($50 billion US dollars) annually, has more than 2,000 locations nationwide.
Arrayit CEO Rene Schena states, “Completing an allergy testing pilot program for a major retailer advances our clinical initiatives. Arrayit personalized allergy testing, in the context of 1,700 sales reps and a large retail chain, would accelerate our mission to provide health and wellness information to millions of American households”.
Thank you and holy cow. So the run rate is about $192,838,548 invoiced over 12 months. Mark's billing guidance of $2 million/week totals $104,000,000 annually, so at this run rate he would BEAT his own guidance by $88,838,548 or about 85.4%.
It seems to me the amounts billed will only continue to increase since the lab services are just now getting out of the gate.
Wow. So darn sad and depressing.
Hello? Most of the "investing world" doesn't even know about Arrayit, not yet anyway. Exciting times coming up.
"We haven't heard?" Well, I just don't think the credentialing company is going to contact you about anything. And it's a good thing Mark didn't divulge the name of the company!
lol
Holy cannoli, TravO!. Thank you for sharing/confirming.
:))
That can't happen because RRBB resigned. Period. Time to move onward and upward with Nasdaq as the goal in 2019 or 2020.
That sounds about right. It shouldn't be too much longer.
That is not true. It's a fact that the new auditor may pick up where RRBB left off (research by MikeCr on this very subject has been posted on this board). I believe they needed to just finish up FY2018 and then Q1 of 2019. That would bring ARYC current.
How can an "opinion" be a "fact?" Something to ponder.
Your post might express your opinion but certainly NO FACTS.
Well I think you are WRONG on both counts, and will leave it at that.
Only time will tell.
But Janice, "no audit reports were issued" does not mean that no audits were completed. We ALL know how close they were, but apparently there was some further "documentation" needed, which caused the April freak-out. We also know that they wanted to become current by filing all audited reports at the same time.
Seems to me the 8K was carefully worded for good reasons, and that the new auditor should be able to pick up where RRBB left off.
Maybe all the hungry ask slappers have no more money because they have been accumulating since early April.
I am well aware of that, but there is no way of knowing the actual revenue until we see the audited financials or if the company decides to share some actual receivables via PR or Twitter or 8K.
We do know that if Medicare doesn't pay entirely, a supplemental plan would most likely cover the rest, and I would imagine if there is no supplemental plan, the patient would be billed for the balance. Only time will tell that tale.
:))
One thing you should not forget, ARYC is still very much under the radar. Low volume days are never surprising. Wall Street and larger investors and/or institutions don't have a clue about what is going on at ARYC unless they have deliberately chosen to follow the company via its Twitter posts and occasional PRs. Eventually, the entire investing community will stand up and take notice.
Yes they will.
During his studies at Berkeley, Schena showed that changes in citrate synthase expression cause changes in flux through the citric acid cycle.[1] This work showed the importance of rate limiting steps in enzymatic pathways. As a graduate student at UCSF, Schena discovered the evolutionary conservation of cellular mechanisms across eukaryotic evolution by demonstrating the conservation of mammalian glucocorticoid receptor function in the yeast Saccharomyces cerevisiae.[2] At Stanford, Schena pioneered a new field of science (microarray technology) as the first author on the Stanford team publication in the journal Science demonstrating that complementary DNA molecules immobilized on glass could be used to measure gene expression in the flowering plant Arabidopsis thaliana.[3] The modern microarray industry and solid-phase DNA sequencing industry have drawn heavily from the 1995 Science paper. More than 42,000 peer-reviewed microarray publications have appeared in the scientific literature since 1995.[4]
Schena has written four books on microarrays,[5][6][7][8] including the first textbook on the subject,[9] and has been featured by journalists in interviews covered by the print media, radio and television.[10] Schena has pioneered an extensive line of microarray products and services at Arrayit[clarification needed]. Schena is the inventor of Variation Identification Platform (VIP) technology, which is capable of genotyping up to 80,000 patients in a single microarray test.[11] Schena has taken an active role in healthcare reform in the United States by promoting the importance of technical innovation as a means of improving the quality and accessibility of healthcare and controlling its cost.[12] Schena is considered the foremost authority on microarray technology, referred to as the "Father of Microarray Technology".[13]
In 2001, Schena was featured on the Nova television documentary "Cracking the Code of Life", a two-hour special hosted by ABC News Nightline correspondent Robert Krulwich.[14] Schena first introduced microarrays as pre-symptomatic diagnostic tools on the 2001 Nova program. Schena holds the first and second positions on "The Microarray Family Tree", a historiograph of 13 influential papers published in the microarray field, written by Eugene Garfield.[15] The Scientist also credited Schena with creating the first array.[16] Schena was proclaimed the "Father of Microarrays" in an article written by Lloyd Dunlap, contributing editor of Drug Discovery News, in an account of Schena's pioneering work to decipher Parkinson's disease.[17] Schena and Rene Schena reside in Los Altos, California.
Well, what Mike posted about the new auditor not having to start from scratch should make you happy and hopeful.
What really speaks volumes is that ARYC is currently billing an average of $3,722,465 PER WEEK.
That is very wonderful. I was going to research that very subject, so thank you for sharing that. If all goes well, the new auditor will just have to pick up where RRBB auditor left off.
OK duh. If they hadn't paid the rent for 927 Thompson Place, Sunnyvale, CA, then they would not still be there. Landlords are too greedy to allow tenants to stay under those circumstances.
Or maybe they made a huge deposit on purchasing the building and everyone is happy and excited.
Arrayit is planning on PURCHASING the building. If they had rent problems last year, then that is in the PAST. With $14,889,863 billed in 4 weeks time, those days are history. The rent they have been paying is very high, so it will be a beautiful thing if they can pull that off.
Greedy landlords.
According to Dr. Schena, there will be no r/s. If necessary, the company may buy back shares and retire them to the treasury, after ARYC becomes current of course.
Yup, and headed for the NASDAQ.
Daisy-land.
Daisy.
May as well be asking a dandelion if “she loves me”.
Totally agree James...sorry I can't PM.
Not a wrong ASSumption. I am right and you are wrong. It's OK to admit it.
:))
Not going to argue with you. Insider trading now is RISKY, and Mark is aware of that and has even indicated they will be BUYING shares when ARYC becomes CURRENT.
Geeeeez.
There are many PCAOB certified auditors in the Sunnyvale, CA, area. New Jersey is clear across the country, and it wasn't ARYC's choice of an auditor anyway. It could be a matter of handing over the documentation prepared and delivered to RRBB and tying up some loose ends.
:))
That is NOT an opinion, it's a fact. It would be very RISKY for any of them to participate in the buying or selling of stock when they have not filed financials for a few years and have other MAJOR things going on behind the scenes.
I post the truth on these boards. Wish everyone did.
Wrong. Insider buying would be illegal because they have loads of information not yet released to the public. Our friend, Jason, is NOT AN INSIDER. He is a private investor who can do whatever he want, whenever he wants.
Insider trading during this period would be ILLEGAL.
No one could possibly believe Mark is making up those numbers. He is not insane. He doesn't want to spend any time in the joint, and you can trust me on that.
The past is the past. It's all about the future now.
Of course I am happy.
No those are REAL numbers, not a "nice try." Believe them or not. OK, so let's review:
So Mark BEAT his own weekly billing guidance by over 86%. Nice going, ARYC and thank you HYS.
Weekly average for 4 weeks = $3,722,465
Amount over $2 million guidance = $1,722,465
Simply incredible!
You must have missed my post from last week:
"But in addition to the preferred shares, Mark is also a commoner like us with 2 million shares, Rene has 1 million, and Todd Martinsky 1.5 million. Their shares were purchased at much higher prices when the O/S was substantially lower."